Global Kidney Fibrosis Pipeline Review - H2 2019 - ResearchAndMarkets.com

DUBLIN--()--The "Kidney Fibrosis - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

This review provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 35 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Kidney Fibrosis - Overview
  • Kidney Fibrosis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Kidney Fibrosis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Kidney Fibrosis - Companies Involved in Therapeutics Development
  • Kidney Fibrosis - Drug Profiles
  • Kidney Fibrosis - Dormant Projects
  • Kidney Fibrosis - Discontinued Products
  • Kidney Fibrosis - Product Development Milestones
  • Appendix

Companies Mentioned

  • AdAlta Ltd
  • Algernon Pharmaceuticals Inc
  • Angion Biomedica Corp
  • Aravive Inc
  • BiOrion Technologies BV
  • Blade Therapeutics Inc
  • Cellmid Ltd
  • Curacle Co Ltd
  • Ember Therapeutics Inc (Inactive)
  • Epigen Biosciences Inc
  • Evotec SE
  • Future Medicine Co Ltd
  • Galapagos NV
  • Galectin Therapeutics Inc
  • GenKyoTex SA
  • iBio Inc
  • Isarna Therapeutics GmbH
  • Kadmon Corp LLC
  • Liminal BioSciences Inc
  • Max Biopharma Inc
  • MedPacto Inc
  • Mission Therapeutics Ltd
  • NB Health Laboratory Co Ltd
  • Novo Nordisk AS
  • Oasis Pharmaceuticals LLC
  • Osteoneurogen Inc
  • Pharmaxis Ltd
  • Redx Pharma Plc
  • Sanofi
  • Scholar Rock Inc
  • Senolytic Therapeutics Inc
  • TiumBio Co Ltd
  • Transcenta Holding Ltd
  • Vascular Biogenics Ltd
  • Vectus Biosystems Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/dk26t5

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900